Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.42 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.42 |
| ▸ | ITGAL | P20701 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6761995 | 0.99 | LMNA (0.47) | LMNAALDH1A1BLMNPSR1NOD2 | |
| SCHEMBL6763799 | 0.90 | LMNA (0.47) | LMNAALDH1A1BLMNPSR1NOD2 | |
| SCHEMBL6761155 | 0.89 | LMNA (0.46) | LMNAALDH1A1BLMNPSR1NOD2 | |
| SCHEMBL6759536 | 0.88 | PKM (0.46) | LMNAALDH1A1KMT2AL3MBTL1KDM4E | |
| SCHEMBL6762867 | 0.88 | LMNA (0.46) | LMNAALDH1A1BLMNPSR1NOD2 | |
| SCHEMBL5019657 | 0.87 | SLC6A4 (0.51) | LMNAALDH1A1BLMNPSR1NOD2 | |
| SCHEMBL6759484 | 0.86 | LMNA (0.44) | LMNAALDH1A1BLMNPSR1NOD2 | |
| SCHEMBL6762671 | 0.84 | ITGB2 (0.43) | LMNAALDH1A1BLMNPSR1NOD2 | |
| SCHEMBL6766233 | 0.84 | LMNA (0.45) | LMNAALDH1A1BLMNPSR1NOD2 | |
| SCHEMBL6763050 | 0.83 | LMNA (0.42) | LMNAALDH1A1BLMNPSR1NOD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040192680-A1 | Novel amides that activate soluble guanylate cyclase | ABBOTT LABORATORIES | 2004-09-30 | — | — | US | claimed |
| WO-2004060859-A2 | NOVEL AMIDES THAT ACTIVATE SOLUBLE GUANYLATE CYCLASE | ABBOTT LABORATORIES (US) | 2004-07-22 | — | — | WO | claimed |
| US-20040121994-A1 | Novel amides that activate soluble guanylate cyclase | ABBOTT LABORATORIES | 2004-06-24 | — | — | US | claimed |
| US-20040192680-A1 | Novel amides that activate soluble guanylate cyclase | ABBOTT LABORATORIES | 2004-09-30 | — | — | US | disclosed |
| WO-2004060859-A2 | NOVEL AMIDES THAT ACTIVATE SOLUBLE GUANYLATE CYCLASE | ABBOTT LABORATORIES (US) | 2004-07-22 | — | — | WO | disclosed |
| US-20040121994-A1 | Novel amides that activate soluble guanylate cyclase | ABBOTT LABORATORIES | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121994-A1 | Novel amides that activate soluble guanylate cyclase | GUCY1A1, GUCY1B1, GUCY1A2 | LMNA 2027/4885ALDH1A1 510/4885BLM 3751/4885 |
| US-20040192680-A1 | Novel amides that activate soluble guanylate cyclase | GUCY1A1, GUCY1B1, GUCY1A2 | LMNA 2027/4885ALDH1A1 510/4885BLM 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.